| Active substance | glofitamab |
| Holder | nv Roche sa |
| Status | closed |
| Indication | as monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), after two or more lines of systemic therapy |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 19/04/2024 |